Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bromperidol→

Bromperidol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10457-90-6
Molecular formula
C21H23BrFNO2
Molecular weight
420.315 g/mol
Drug class
Butyrophenone typical antipsychoticdopamine D2-receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors in central dopaminergic pathways, reducing dopaminergic neurotransmission associated with psychotic symptoms. Extrapyramidal and prolactin-related effects are consistent with D2 blockade.
Indications / reported uses
  • Treatment of schizophrenia and other psychotic disorders in countries where bromperidol is authorised; current availability and exact indications are jurisdiction-specific

Sources: NLM MeSH — Bromperidol · PubMed — Bromperidol clinical pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bromperidol Environmental Risk Assessment (ERA) (the Bromperidol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.